Joel Neal, MD
Enriched profileProfessor of Medicine (Oncology), Division of Oncology, Stanford Cancer Institute · Stanford University School of Medicine
Joel Neal is Professor of Medicine (Oncology), Division of Oncology, Stanford Cancer Institute at Stanford University School of Medicine. OpenAlex indexes 601 publications with 20,439 citations (h-index 56); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 27 Aug 2026
Joel Neal, M.D., PH.D., is Professor of Medicine (Oncology), Division of Oncology, Stanford Cancer Institute at Stanford University School of Medicine. The public record shows 601 publications with 20,439 citations (h-index 56), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 25 companies.
- Most recent indexed publication: 2026 · JCO oncology practice
- Top research focus: Lung Cancer Treatments and Mutations
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 25 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 38 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 175.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Sponsor: Nuvalent Inc.
Industry payments
Updated 27 Aug 2026
25 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Iovance Biotherapeutics, Inc.Program year20253 payments$10,875openpaymentsdata.cms.gov ↗
- TAIHO ONCOLOGY, INC.Program year20254 payments
- Janssen Biotech, Inc.Program year20258 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
51.1%Kinase inhibitor51.1%Tagrisso100%Part D<11 patientsNervous system
25.5%Phenothiazine25.5%Prochlorperazine Maleate100%Part D≥11 patientsCardiovascular
23.4%Statin23.4%Rosuvastatin Calcium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
102 congress contributions (2010–2025) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract LB399: Trop-2 expression and association with efficacy in patients treated with sacituzumab govitecan + pembrolizumab +/- carboplatin in the EVOKE-02 study of non-small cell lung cancer
AACR Annual Meeting
AACR2025Co-authorLate-breaking - Digital pathology–based AI spatial biomarker to predict outcomes for immune checkpoint inhibitors in advanced non-small cell lung cancer.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Tobacco Use and Cessation Patterns Among Cancer Survivors: Results From Nine ECOG-ACRIN Cancer Research Group Trials.
JCO oncology practice
Article2026 - First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 Study.
Clinical cancer research
Clinical Trial2026 - Air pollution and the risk of second primary lung cancer among lung cancer survivors: the prospective UK Biobank cohort study.
British journal of cancer
Article2026 - Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal of clinical oncology
Article2026
Most-cited works
by citation count (OpenAlex)- 01An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverageArticle2,281 citations2014
- 02
- 03Integrated digital error suppression for improved detection of circulating tumor DNAArticle1,157 citations2016
- 04
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/joel-neal-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - X / Twitter
x.com/JoelNealMD
- LinkedIn
linkedin.com/in/joel-neal-536b8b1b
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
voicesoftheiaslc.gv-one.com/video.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →voicesoftheiaslc.gv-one.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →stanfordhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
- Ph.D.
Tumor Cell Biology, Northwestern University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
Editorial & leadership roles
journal and society appointments- Member
International Association for the Study of Lung Cancer (IASLC)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗ - Thoracic Committee Member
ECOG-ACRIN
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.ecog-acrin.org ↗ - Study Chair
ECOG-ACRIN trials EA5152 and EA5191
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.ecog-acrin.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →blog.ecog-acrin.org ↗
Secondary affiliations
appointments beyond the home institution- Member
Stanford Bio-X
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →biox.stanford.edu ↗ - Faculty Member
Center for Asian Health Research and Education (CARE), Stanford Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asianhealth.stanford.edu ↗
Media & interviews
press, podcasts and appearances- ASCO 2026: Joel Neal
MD, PhD, Shares CHRYSALIS-2 Cohort C Insights for Atypical EGFR-Mutated NSCLC (video interview)
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lungcancerstoday.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- Presentation and Molecular Testing of Lung Cancer Without a Smoking History
with Dr. Joel Neal (YouTube video)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Paul Heidenreich, MD
Stanford University School of Medicine
Alan Schatzberg, MD
Stanford University School of Medicine
Mark Pegram, MD
Stanford University School of Medicine
Vibeke Strand, MD
Stanford University School of Medicine